Table 1.

Baseline characteristics and responses to treatment with rituximab for all subjects grouped according to baseline anti-PLA2R positivity and clearance versus persistence of anti-PLA2R at 12 months after treatment

AgeGenderDisease Duration (Months)Serum Creatinine (mg/dl)Creatinine Clearance (ml/min per 1.73 m2)Baseline Anti-PLA2R12-Month Anti-PLA2RBaseline Proteinuria (g/d)Outcome (12 Months)Outcome (24 Months)
Group 1: anti-PLA2R positive; clearance by 12 months
Summary47 ± 1014:3111.5 ± 0.574 ± 3222,462a0b11.8
Group 2: anti-PLA2R positive; persistence at 12 monthsc
Summary49 ± 106:011.51.6 ± 0.675 ± 2630,231a11,625b14.98
Group 3: anti-PLA2R negative
Summary47 ± 108:291.4 ± 0.587 ± 3409.86
  • Baseline and 12-month anti-PLA2R levels are presented in arbitrary densitometric units. Summary data are presented as means ± standard deviation or medians when appropriate. M, male; F, female; RL, relapse; ΔIST, change in immunosuppressive therapy; NA, not available.

  • Baseline and 12 month anti-PLA2R levels were significantly lower in group 1 than in group 2 (aP = 0.001; bP < 0.001). There were no other statistically significant differences between groups 1 and 2.

  • cTwelve-month serum samples were not available for subjects 24 and 25. They are included in group 2 for the purposes of this table, but they are not included in the statistical analyses or the summary data because we were unable to determine if there was a response in anti-PLA2R or not.

  • dThese two patients had faint visible bands that fell below the detection threshold of 1000 densitometric units when assayed at 1:25.

  • eThese bands were undetectable at a 10-second exposure but were visible at longer exposures; the anti-PLA2R level was extrapolated by calculating percentage of baseline value at the 10-second and longer exposure.

  • f“Limited” response (>50% decrease from baseline proteinuria but still >3.5 g/d).